N
Nuclidium
Biotech & Life Sciences · Basel, Switzerland · Founded 2017
Setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer… MoreLess
Nuclidium AG is a clinical-stage biotechnology company specializing in the development of copper-based radiopharmaceuticals. The firm is focused on creating a new standard in precision oncology by developing next-generation solutions for both the diagnosis and treatment of cancer, a concept known as theranostics.
The company's platform is centered on the use of copper isotopes, specifically 61Cu for PET imaging (diagnosis) and 67Cu for therapy. This approach reportedly offers significant advantages, including higher absorption of the agent by tumors and safer radiation profiles for patients. Nuclidium is advancing a pipeline of these targeted radiopharmaceuticals and has announced positive Phase 1 results for its novel PET imaging agent, 61Cu-NuriPro.
The business model appears to be focused on research and development, advancing its product pipeline through clinical trials. To support this, the company engages in strategic partnerships, such as its collaboration with Guerbet, to further the development and potential commercialization of its targeted copper-based radiotheranostics. The company operates in the specialized and high-growth market of radiopharmaceuticals and precision oncology.
Keywords: Radiopharmaceuticals, Theranostics, Precision Oncology, Copper Isotopes, Cancer Diagnosis, Cancer Treatment, Clinical-Stage, Biotechnology, PET Imaging, 67Cu
Company overview
Nuclidium company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Basel, Switzerland
- Employees
- 33
- Open positions
- 1
- Dealroom signal
- 93.8
Valuation & funding
Nuclidium funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2026 | $31M | $476M | Bayern Kapital · NRW.BANK · Vives Partners · DeepTech & Climate Fonds | ↗ |
| SERIES BOther financing | Jul 2025 | $95M | $381M | European Investment Bank · NEVA SGR · Wellington Partners · Kurma Partners | ↗ |
| EARLY VCOther financing | May 2024 | $0 | — | Guerbet | ↗ |
| GRANTOther financing | Mar 2022 | $2.2M | — | European Commission | ↗ |
| SERIES AOther financing | Jun 2021 | $2.9M | $12M | Turos Capital | — |
Growth signals
Nuclidium website traffic
Latest recorded traffic for Nuclidium is 3.1K monthly website visits, up 273.5% over the last three months. Nuclidium's team grew 32% over the past year.
Hiring
Open positions at Nuclidium
Current openings linked to this company in Dealroom.
Comparisons
Nuclidium compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Nuclidium's talent
Source: Dealroom Talent Intelligence.
Investors
12 investors on Nuclidium's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Nuclidium has talent and traffic
team presence
In the news
Latest news about Nuclidium
Recent press, funding announcements, and product moves mentioning Nuclidium — open to read from the original sources.
Market sentiment
What the market is saying about Nuclidium
An AI-synthesized read of the highest-engagement posts about Nuclidium on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nuclidium’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.